0001104659-18-048862.txt : 20180801
0001104659-18-048862.hdr.sgml : 20180801
20180801192145
ACCESSION NUMBER: 0001104659-18-048862
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180730
FILED AS OF DATE: 20180801
DATE AS OF CHANGE: 20180801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mirabelli Christopher
CENTRAL INDEX KEY: 0001262326
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37990
FILM NUMBER: 18986196
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 301
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER NAME:
FORMER CONFORMED NAME: MIRAELLI CHRISTOPHER
DATE OF NAME CHANGE: 20030904
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LEAP THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001509745
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274412575
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 47 THORNDIKE STREET
STREET 2: SUITE B1-1
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617 252 4343
MAIL ADDRESS:
STREET 1: 47 THORNDIKE STREET
STREET 2: SUITE B1-1
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Dekkun Corp
DATE OF NAME CHANGE: 20110107
4
1
a4.xml
4
X0306
4
2018-07-30
0
0001509745
LEAP THERAPEUTICS, INC.
LPTX
0001262326
Mirabelli Christopher
C/O LEAP THERAPEUTICS, INC.
47 THORNDIKE STREET SUITE B1-1
CAMBRIDGE
MA
02141
1
1
1
0
CEO, President and COB
Warrant (Right to Buy)
6.085
2018-07-30
4
J
0
21369
0
A
2017-11-14
2024-11-14
Common Stock
21369
21369
I
See Footnotes
Pro rata distribution from HealthCare Ventures IX, L.P. ("HCV IX") to its limited partner, Nine Capital Partners, LLC. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor are the Managing Members of Nine Capital Partners, LLC, and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC. Dr. Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.
The reporting person is also (i) a Managing Director of HealthCare Partners IX, LLC, which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HCV IX, (ii) a Managing Director of HealthCare Partners VIII, LLC, which is the General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"), and (iii) a Managing Director of HCV Strategic LLC, which is the General Partner of HealthCare Ventures Strategic Fund, L.P. ("HCV SF"). HCV IX continues to hold 3,573,376 shares of common stock, HCV VIII continues to hold 2,618,406 shares of common stock, and HCV SF continues to hold 343,889 shares of common stock, representing 24.3%, 17.8%, and 2.3%, respectively, and 44.5% in the aggregate, of the outstanding shares of common stock.
/s/ Douglas E. Onsi as attorney-in-fact for Christopher Mirabelli
2018-08-01